Hepatitis e virus seroprevalence and correlates of anti-HEV IgG antibodies in the Rakai District, Uganda

the Rakai Health Sciences Program

Research output: Contribution to journalArticle


A cross-sectional study was conducted of 500 human immunodeficiency virus (HIV)-infected adults frequency matched on age, sex, and community to 500 HIV-uninfected individuals in the Rakai District, Uganda to evaluate seroprevalence of anti-hepatitis E virus (HEV) IgG antibodies. HEV seroprevalence was 47%, and 1 HIV-infected individual was actively infected with a genotype 3 virus. Using modified Poisson regression, male sex (prevalence ratios [PR] = 1.247; 95% confidence interval [CI], 1.071-1.450) and chronic hepatitis B virus infection (PR = 1.377; 95% CI, 1.090-1.738) were associated with HEV seroprevalence. HIV infection status (PR = 0.973; 95% CI, 0.852-1.111) was not associated with HEV seroprevalence. These data suggest there is a large burden of prior exposure to HEV in rural Uganda.

Original languageEnglish (US)
Pages (from-to)785-789
Number of pages5
JournalJournal of Infectious Diseases
Issue number5
Publication statusPublished - Mar 1 2018



  • Hepatitis E virus
  • HEV seroprevalence
  • Rakai
  • Uganda
  • Viral hepatitis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Cite this